Biomerica Inc
BMRA2.650USD
+0.030+1.15%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
7.46MMarket Cap
LossP/E TTM
More Details of Biomerica Inc Company
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Biomerica Inc Info
Ticker SymbolBMRA
Company nameBiomerica Inc
IPO dateMar 17, 1980
CEOIrani (Zackary S)
Number of employees53
Security typeOrdinary Share
Fiscal year-endMar 17
Address17571 Von Karman Avenue
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92614
Phone19493792875
Websitehttps://biomerica.com/
Ticker SymbolBMRA
IPO dateMar 17, 1980
CEOIrani (Zackary S)
Company Executives of Biomerica Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
166.63K
--
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
24.53K
--
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
21.25K
--
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
10.00K
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Allen C. Barbieri
Mr. Allen C. Barbieri
Executive Vice Chairperson of the Board and Corporate Secretary
Executive Vice Chairperson of the Board and Corporate Secretary
--
--
Dr. Jane F. Emerson, M.D., Ph.D.
Dr. Jane F. Emerson, M.D., Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Zackary S. Irani
Mr. Zackary S. Irani
Chief Executive Officer, Director
Chief Executive Officer, Director
166.63K
--
Mr. Gary Lu
Mr. Gary Lu
Chief Financial Officer
Chief Financial Officer
24.53K
--
Mr. David Moatazedi
Mr. David Moatazedi
Independent Director
Independent Director
21.25K
--
Mr. Eric Chin
Mr. Eric Chin
Independent Director
Independent Director
10.00K
--
Mr. Gary M. Huff
Mr. Gary M. Huff
Independent Director
Independent Director
--
--
Mr. Scott Madel
Mr. Scott Madel
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Clinical Lab
3.18M
59.89%
Contract Manufacturing
1.07M
20.15%
OTC
1.05M
19.75%
Physicians’ Office
11.00K
0.21%
By RegionUSD
Name
Revenue
Proportion
Asia
1.72M
32.35%
United States
1.66M
31.22%
Europe
1.30M
24.42%
Middle East
630.00K
11.86%
South America
8.00K
0.15%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Lab
3.18M
59.89%
Contract Manufacturing
1.07M
20.15%
OTC
1.05M
19.75%
Physicians’ Office
11.00K
0.21%
Shareholding Stats
Updated: Tue, Nov 25
Updated: Tue, Nov 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Irani (Zackary S)
5.65%
Barbieri (Allen)
1.26%
Emerson (Jane)
1.02%
Lu (Gary)
0.83%
Moatazedi (David)
0.72%
Other
90.51%
Shareholders
Shareholders
Proportion
Irani (Zackary S)
5.65%
Barbieri (Allen)
1.26%
Emerson (Jane)
1.02%
Lu (Gary)
0.83%
Moatazedi (David)
0.72%
Other
90.51%
Shareholder Types
Shareholders
Proportion
Individual Investor
10.38%
Investment Advisor
1.84%
Investment Advisor/Hedge Fund
0.78%
Hedge Fund
0.36%
Research Firm
0.03%
Other
86.61%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
61
88.80K
11.10%
--
2025Q3
66
109.78K
12.53%
+19.30K
2025Q2
64
90.48K
15.22%
-57.30K
2025Q1
68
147.78K
21.33%
-341.18K
2024Q4
67
244.57K
22.09%
-15.39K
2024Q3
66
259.96K
25.76%
-100.07K
2024Q2
66
360.04K
29.98%
-224.63K
2024Q1
64
584.66K
28.76%
-20.09K
2023Q4
60
562.02K
30.44%
-39.83K
2023Q3
60
602.09K
33.14%
-52.42K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Moatazedi (David)
--
0%
-10.63K
-100.00%
Sep 26, 2025
The Vanguard Group, Inc.
21.13K
0.74%
+1.00
+0.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
21.66K
0.75%
+2.09K
+10.68%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
18.64K
0.65%
+1.00
+0.01%
Jun 30, 2025
Coste (Catherine)
16.10K
0.1%
+10.63K
+194.10%
Dec 13, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 16, 2025
Merger
8→1
Date
Type
Ratio
Apr 16, 2025
Merger
8→1
FAQs
Who are the top five shareholders of Biomerica Inc?
The top five shareholders of Biomerica Inc are:
Moatazedi (David) holds 0.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 21.13K shares, accounting for 0.74% of the total shares.
Geode Capital Management, L.L.C. holds 21.66K shares, accounting for 0.75% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 18.64K shares, accounting for 0.65% of the total shares.
Coste (Catherine) holds 16.10K shares, accounting for 0.10% of the total shares.
Moatazedi (David) holds 0.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 21.13K shares, accounting for 0.74% of the total shares.
Geode Capital Management, L.L.C. holds 21.66K shares, accounting for 0.75% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 18.64K shares, accounting for 0.65% of the total shares.
Coste (Catherine) holds 16.10K shares, accounting for 0.10% of the total shares.
What are the top three shareholder types of Biomerica Inc?
The top three shareholder types of Biomerica Inc are:
Irani (Zackary S)
Barbieri (Allen)
Emerson (Jane)
Irani (Zackary S)
Barbieri (Allen)
Emerson (Jane)
How many institutions hold shares of Biomerica Inc (BMRA)?
As of 2025Q4, 61 institutions hold shares of Biomerica Inc, with a combined market value of approximately 88.80K, accounting for 11.10% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.42%.
What is the biggest source of revenue for Biomerica Inc?
In FY2025, the Clinical Lab business generated the highest revenue for Biomerica Inc, amounting to 3.18M and accounting for 59.89% of total revenue.
